Drug Profile
Hyperlipidaemia gene therapy - Armata Pharmaceuticals
Alternative Names: AAV-VLDLRLatest Information Update: 14 May 2019
Price :
$50
*
At a glance
- Originator Targeted Genetics Corporation
- Developer AmpliPhi Biosciences Corporation; Targeted Genetics Corporation
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action LDL receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hyperlipidaemia
Highest Development Phases
- No development reported Hyperlipidaemia
- Discontinued Hyperlipoproteinaemia type II
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in USA
- 09 Mar 2011 Targeted Genetics Corporation is now called AmpliPhi Biosciences